Simvastatin with or without ezetimibe in familial hypercholesterolemia.

  title={Simvastatin with or without ezetimibe in familial hypercholesterolemia.},
  author={John J Kastelein and Fatima Akdim and Erik S. G. Stroes and Aeilko H. Zwinderman and Michiel L. Bots and Anton F. H. Stalenhoef and Frank L. J. Visseren and Eric J.G. Sijbrands and Mieke D. Trip and Evan A. Stein and Daniel Gaudet and Rapha{\"e}l Duivenvoorden and Enrico P. Veltri and Adrian D Marais and Eric de Groot},
  journal={The New England journal of medicine},
  volume={358 14},
BACKGROUND Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. METHODS We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode… 

Figures and Tables from this paper

Statin/ezetimibe combination therapy: emerging evidence.

The Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis (ARBITER 6-HALTS) study comparing niacin with ezetimibe as an add on to statin therapy showed clear superiority of the former, however, there are methodological reservations regarding both of these trials.

The ENHANCE trial: analysis and clinical significance

Despite achieving a significant differential reduction in LDL-C, no regression in carotid intima-media thickness was observed at the end of the 2-year follow-up period and the results of the ongoing outcome trials with ezetimibe are needed to know for certain the effect of ezettimibe on clinical outcomes.

Extended-release niacin or ezetimibe and carotid intima-media thickness.

This comparative-effectiveness trial shows that the use of extended-release niacin causes a significant regression of carotid intima-media thickness when combined with a statin and that niac in is superior to ezetimibe.

Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial.

Combined therapy with fluvastatin 20 mg plus ezetimibe 10 mg daily resulted in a significant improvement in changes in the estimated glomerular filtration rate, and side-effect and safety profiles were similar in the two groups.

Ezetimibe therapy for dyslipidemia: an update.

The results of the ongoing IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) which compares ezetimibe plus simVastatin with simvastatin monotherapy with regard to CVD outcomes after acute coronary syndromes should further elucidate the effect of ezETimibe on CVD events.

Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?

Whether ezetimibe can add to the benefits of statins on atherosclerosis and cardiovascular risk reduction in relation to further LDL-C lowering and lipid-modifying properties is discussed.

Ezetimibe plus simvastatin for the treatment of hypercholesterolemia

The controversy around the role of ezetimibe is broach, particularly in light of the results of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), which is the first to demonstrate incremental cardiovascular risk reduction with the addition of eZetIMibe to simvastatin.

[Lower is better: ENHANCE affair].

The experience of the ENHANCE trial suggests to pharmaceutical companies, researchers, clinicians, scientific companies and media a deep meditation in order to avoid in the future similar problems in the management of results of medical research.

The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases

The efficacy and safety of ezetimibe plus statins in all kinds of ASVD subtypes and their related diseases, mainly included aortic atherosclerosis, coronary artery disease, cerebrovascular and peripheral artery diseases are summarized.



Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin.

High-dose simvastatin therapy reduces arterial wall IMT in more than two thirds of the patients, with its largest effect on the femoral artery.

Simvastatin Versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans

Four weeks of simvastatin treatment improves endothelial function independently of LDL cholesterol lowering, at least in part by reducing oxidant stress.

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.

ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness

Marked LDL reduction (<100 mg/dL) with a high-potency statin provides superior efficacy for atherosclerosis regression at 1 year, suggesting that marked LDL reduction with synthetic statins may provide enhanced reduction in clinical coronary event rates.

Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the &bgr;-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS)

This is the first randomized trial to show that a low-dose metoprolol CR/XL and fluvastatin can reduce the rate of progression of carotid IMT in clinically healthy, symptom-free subjects with carotids plaque, and suggests that &bgr;-blockers may have a favorable effect on atherosclerosis development.

Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia

In patients with familial hypercholesterolemia, the use of torcetrapib withAtorva statin, as compared with atorvastatin alone, did not result in further reduction of progression of atherosclerosis, as assessed by a combined measure of carotid arterial-wall thickness, and was associated with progression of disease in the common carotids segment.

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins

The addition of extended-release niacin to statin therapy slowed the progression of atherosclerosis among individuals with known coronary heart disease and moderately low HDL-C.